Molecular profiling of an exceptional response to the multitargeted kinase inhibitor sorafenib may have identified a new druggable oncogene in lung cancer.
Molecular profiling of an exceptional response to the multitargeted kinase inhibitor sorafenib may have identified a new druggable oncogene in lung cancer.